Gisbert Javier P, Chaparro María
Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.
Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.
Gastroenterol Hepatol. 2025 Jun-Jul;48(6):502363. doi: 10.1016/j.gastrohep.2025.502363. Epub 2025 Jan 22.
Etrasimod is a synthetic, non-biological, orally administered small molecule sphingosine-1-phosphate receptor (S1PR) modulator. Etrasimod was approved by the Food and Drug Administration in 2023 and by the European Medicine Agency in 2024, constituting a new therapeutic option for the treatment of moderately to severely active ulcerative colitis in patients 16 years of age and older in the European Union. Its efficacy and tolerability have been demonstrated in several clinical trials both as induction and maintenance treatment, as well as in long-term extension studies. This article reviews the pharmacodynamic characteristics of etrasimod, its main differences with biological drugs and other small molecules (janus kinases inhibitors), as well as its clinical efficacy including certain subpopulations such as patients with isolated ulcerative proctitis, and the impact on their quality of life.
埃特拉莫德是一种合成的、非生物的、口服的小分子鞘氨醇-1-磷酸受体（S1PR）调节剂。埃特拉莫德于2023年获得美国食品药品监督管理局批准，并于2024年获得欧洲药品管理局批准，成为欧盟16岁及以上中度至重度活动性溃疡性结肠炎患者治疗的一种新的治疗选择。其疗效和耐受性已在多项作为诱导和维持治疗的临床试验以及长期扩展研究中得到证实。本文综述了埃特拉莫德的药效学特性、与生物药物和其他小分子（Janus激酶抑制剂）的主要差异、其临床疗效（包括某些亚组，如孤立性溃疡性直肠炎患者）以及对患者生活质量的影响。
